Summary
Gilead Sciences, Inc. reported its third-quarter and nine-month results for the period ending September 30, 2000. While total revenues showed growth, increasing by 17% year-over-year for the nine months to $140.3 million, the company continued to operate at a net loss. The net loss for the nine months narrowed to $27.5 million from $57.5 million in the prior year, indicating improving operational efficiency or revenue growth outpacing expense increases. Key revenue drivers included AmBisome product sales and increasing royalties from Tamiflu. The company also saw a significant reduction in selling, general, and administrative expenses, largely due to the absence of merger-related costs from the prior year's NeXstar acquisition. The company's financial position remains strong with $293.2 million in cash, cash equivalents, and marketable securities. A significant event during the period was the conversion of all outstanding convertible subordinated debentures in August 2000, eliminating associated interest expense and strengthening the balance sheet by converting debt to equity. Gilead appears to be managing its liquidity well and is investing heavily in research and development, particularly for its HIV and Hepatitis B programs.
Key Highlights
- 1Total revenues increased by 17% for the first nine months of 2000 to $140.3 million, driven by product sales and royalty income.
- 2Net loss narrowed to $27.5 million for the first nine months of 2000, a significant improvement from $57.5 million in the same period of 1999.
- 3AmBisome sales remain the primary revenue driver, accounting for approximately 94% of product sales, with a reported 14% increase year-over-year for the nine-month period.
- 4Royalty revenues more than doubled for the nine-month period to $19.3 million, benefiting from sales of Tamiflu and AmBisome.
- 5Selling, General, and Administrative (SG&A) expenses decreased by 24% for the nine-month period due to the absence of merger-related costs from the prior year's acquisition.
- 6Research and Development (R&D) expenses increased by 11% for the nine-month period to $88.4 million, reflecting ongoing investment in key development programs like tenofovir for HIV and adefovir for Hepatitis B.
- 7The company's liquidity position is robust, with cash, cash equivalents, and marketable securities totaling $293.2 million as of September 30, 2000.